CN102066333A - 用作σ受体抑制剂的5-甲基-1-(萘-2-基)-1H-吡唑 - Google Patents

用作σ受体抑制剂的5-甲基-1-(萘-2-基)-1H-吡唑 Download PDF

Info

Publication number
CN102066333A
CN102066333A CN200980122589XA CN200980122589A CN102066333A CN 102066333 A CN102066333 A CN 102066333A CN 200980122589X A CN200980122589X A CN 200980122589XA CN 200980122589 A CN200980122589 A CN 200980122589A CN 102066333 A CN102066333 A CN 102066333A
Authority
CN
China
Prior art keywords
compound
formula
methyl
pyrazol
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200980122589XA
Other languages
English (en)
Chinese (zh)
Inventor
安东尼·托伦斯霍维尔
玛莉亚·罗萨·库韦莱斯-阿尔蒂森特
玛莉亚·何塞·普瑞特尔桑切斯
玛莉亚·马格达兰纳·博尔达斯格拉波特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Pharmaceuticals SA
Original Assignee
Laboratorios del Dr Esteve SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios del Dr Esteve SA filed Critical Laboratorios del Dr Esteve SA
Publication of CN102066333A publication Critical patent/CN102066333A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN200980122589XA 2008-04-25 2009-04-27 用作σ受体抑制剂的5-甲基-1-(萘-2-基)-1H-吡唑 Pending CN102066333A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08384005.8 2008-04-25
EP08384005A EP2113501A1 (en) 2008-04-25 2008-04-25 5-Methyl-1-(naphthalen-2-YL)-1H-Pyrazoles useful as sigma receptor inhibitors
PCT/EP2009/055065 WO2009130331A1 (en) 2008-04-25 2009-04-27 5-methyl-1-(naphthalen-2-yl)-1h-pyrazoles useful as sigma receptor inhibitors

Publications (1)

Publication Number Publication Date
CN102066333A true CN102066333A (zh) 2011-05-18

Family

ID=39739580

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980122589XA Pending CN102066333A (zh) 2008-04-25 2009-04-27 用作σ受体抑制剂的5-甲基-1-(萘-2-基)-1H-吡唑

Country Status (11)

Country Link
US (1) US8492425B2 (https=)
EP (2) EP2113501A1 (https=)
JP (1) JP2011518811A (https=)
KR (1) KR20110006697A (https=)
CN (1) CN102066333A (https=)
AU (1) AU2009239906A1 (https=)
BR (1) BRPI0910679A2 (https=)
CA (1) CA2722256A1 (https=)
MX (1) MX2010011674A (https=)
RU (1) RU2010147918A (https=)
WO (1) WO2009130331A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105377257A (zh) * 2013-06-26 2016-03-02 埃斯蒂维实验室股份有限公司 σ受体配体在预防和治疗与间质性膀胱炎/膀胱疼痛综合征(IC/BPS)相关疼痛中的应用
CN106999473A (zh) * 2014-12-15 2017-08-01 埃斯蒂文博士实验室股份有限公司 σ受体配体在骨关节炎中的用途

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2361904A1 (en) * 2010-02-04 2011-08-31 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride and crystalline forms thereof
BR112012012456A2 (pt) * 2009-11-25 2020-08-11 Laboratorios Del Dr. Esteve, S.A. sal de 4-[2-[[5-metil-1-(2-naftalenil)-1h-pirazol-3-il]oxi]etil]morfolina,processo para a preparação do sal de cloridrato, composição farmacêutica e sal de cloridrato
SG10201500832PA (en) * 2010-02-04 2015-04-29 Esteve Labor Dr 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2395003A1 (en) 2010-05-27 2011-12-14 Laboratorios Del. Dr. Esteve, S.A. Pyrazole compounds as sigma receptor inhibitors
EP2418192A1 (en) * 2010-07-30 2012-02-15 Esteve Química, S.A. Intermediates for the preparation of 1-aryl-pyrazol-3-one compounds useful as sigma receptors inhibitors
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2426111A1 (en) * 2010-08-09 2012-03-07 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms
EP2460804A1 (en) * 2010-12-03 2012-06-06 Laboratorios Del Dr. Esteve, S.A. 5-methyl-1-(naphthalen-2-yl)-1h-pyrazole derivatives and their use in potentiating the effect of opioid analgesics
EP2460519A1 (en) * 2010-12-03 2012-06-06 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in bone cancer pain
EP2524694A1 (en) * 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
TW201607538A (zh) 2013-12-17 2016-03-01 以斯提夫博士實驗室股份有限公司 血清素－去甲腎上腺素再攝取抑制劑（ＳＮＲＩＳ）和σ受體配體組合物
EP3174612B1 (en) 2014-08-01 2019-09-04 Smart Billiard Lighting LLC Billiard table lighting and game play monitor
US12345406B2 (en) 2022-02-09 2025-07-01 Blake Martin Interactive LED system for enhancing billiard gameplay

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101010302A (zh) * 2004-08-27 2007-08-01 埃斯蒂维实验室股份有限公司 σ受体抑制剂
EP1829875A1 (en) * 2006-03-01 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Pyrazole derivatives as sigma receptor inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
CA2576144C (en) 2004-08-27 2012-12-11 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
MX2008011016A (es) 2006-03-01 2008-09-08 Esteve Labor Dr Inhibidores de receptor sigma.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101010302A (zh) * 2004-08-27 2007-08-01 埃斯蒂维实验室股份有限公司 σ受体抑制剂
EP1829875A1 (en) * 2006-03-01 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Pyrazole derivatives as sigma receptor inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105377257A (zh) * 2013-06-26 2016-03-02 埃斯蒂维实验室股份有限公司 σ受体配体在预防和治疗与间质性膀胱炎/膀胱疼痛综合征(IC/BPS)相关疼痛中的应用
CN106999473A (zh) * 2014-12-15 2017-08-01 埃斯蒂文博士实验室股份有限公司 σ受体配体在骨关节炎中的用途

Also Published As

Publication number Publication date
EP2285781A1 (en) 2011-02-23
CA2722256A1 (en) 2009-10-29
US8492425B2 (en) 2013-07-23
AU2009239906A1 (en) 2009-10-29
KR20110006697A (ko) 2011-01-20
RU2010147918A (ru) 2012-05-27
MX2010011674A (es) 2010-11-25
US20110118253A1 (en) 2011-05-19
BRPI0910679A2 (pt) 2015-09-29
WO2009130331A1 (en) 2009-10-29
JP2011518811A (ja) 2011-06-30
EP2113501A1 (en) 2009-11-04

Similar Documents

Publication Publication Date Title
CN102066333A (zh) 用作σ受体抑制剂的5-甲基-1-(萘-2-基)-1H-吡唑
DE60219292T2 (de) Pyrazolderivate zur behandlung von hiv
CA2166721C (en) Bicyclic tetrahydro pyrazolopyridines
CN103003267B (zh) 西格玛受体抑制剂
EP1778686B9 (en) Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
CN101621998B (zh) 具有取代的杂环基团的苯并咪唑大麻素激动剂
US20110053982A1 (en) Ether benzylidene piperidine 5-membered aryl carboxamide compounds useful as faah inhibitors
CA2642209A1 (en) Triazolopyridine compounds
US20110144159A1 (en) Ether benzylidene piperidine aryl carboxamide compounds useful as faah inhibitors
CN101395152A (zh) 西格玛受体化合物
JP2740250B2 (ja) ヘテラ―脂肪族カルボクサミド誘導体、その製造方法、該化合物の中間体および該化合物を含有するロイコトリエン拮抗作用を有する薬学的組成物
DE60318874T2 (de) Pyrazolderivate
WO2009127946A1 (en) 4-benzylidene-3-methylpiperidine aryl carboxamide compounds useful as faah inhibitors
KR20080067355A (ko) 염증 치료에 유용한 피라졸
WO2023017451A1 (en) Small molecule sting antagonists
WO2006056848A1 (en) Octahydropyrrolo[3,4-c]pyrrole derivatives
DE60319254T2 (de) Pyrazolamide zur behandlung von hiv-infektionen
CN101006087B (zh) 作为p38MAP激酶抑制剂的三唑并吡啶基硫烷基衍生物
HK1105536B (en) Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110518